The estimated Net Worth of Darren Sherman is at least $1.33 Tisíc dollars as of 17 December 2020. Mr. Sherman owns over 3,000 units of Motus GI Inc stock worth over $1,325 and over the last 7 years he sold MOTS stock worth over $0. In addition, he makes $0 as Independent Director at Motus GI Inc.
Darren has made over 3 trades of the Motus GI Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of MOTS stock worth $2,910 on 17 December 2020.
The largest trade he's ever made was buying 45,000 units of Motus GI Inc stock on 16 February 2018 worth over $225,000. On average, Darren trades about 4,083 units every 86 days since 2018. As of 17 December 2020 he still owns at least 42,746 units of Motus GI Inc stock.
You can see the complete history of Mr. Sherman stock trades at the bottom of the page.
Darren Sherman M.D. serves as Independent Director of the Company. Mr. Sherman has been a director of Motus GI Medical Technologies Ltd., our wholly owned subsidiary, since 2015 and has served on our Board since December 2016. Since May 2018, Mr. Sherman has been President, Chief Operations Officer and a member of the Board of Orchestra BioMed, Inc., a biomedical innovation company focused on developing high impact therapeutic solutions to address major medical conditions where options for high-risk patients are limited or inadequate. Mr. Sherman has over 24 years of management and entrepreneurial experience in the medical technology industry spanning interventional cardiology, cardiac electrophysiology, sudden cardiac death, stroke, surgery, GI, and neurovascular therapies. Since 2009, Mr. Sherman has been Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employs a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Sherman has also served as Chief Technical Officer of Accelerated Technologies, Inc. (ATI), a medical device accelerator company managed by Orchestra Medical Ventures, LLC, since 2008. Until May 2018, Mr. Sherman served as Chief Executive Officer and a director of Caliber Therapeutics, Inc., and Chief Executive Officer and a director of FreeHold Surgical, Inc. From 2009 until 2016, he served on the board of directors of Vivasure Medical Limited, a medical device company based in Galway, Ireland. Prior to joining Orchestra Medical Ventures, LLC, from February 2002 until March 2008, Mr. Sherman held various positions in executive management for Cordis Neurovascular (CNV), a Johnson & Johnson company, including Executive Director R&D and Director of Strategic Marketing for stroke products. He earned a BS degree in Bioengineering from the University of California, San Diego.
Darren Sherman is 48, he's been the Independent Director of Motus GI Inc since 2016. There are 7 older and 2 younger executives at Motus GI Inc. The oldest executive at Motus GI Holdings Inc is Samuel Nussbaum, 71, who is the Independent Director.
Darren's mailing address filed with the SEC is 1301 E Broward Blvd, Fort Lauderdale, FL 33301, USA.
Over the last 7 years, insiders at Motus GI Inc have traded over $2,638,819 worth of Motus GI Inc stock and bought 3,952,265 units worth $13,986,863 . The most active insiders traders include Advisors Llcperceptive Life..., Larry Noracle Partners Lp F... a David P Hochman. On average, Motus GI Inc executives and independent directors trade stock every 33 days with the average trade being worth of $4,105. The most recent stock trade was executed by Andrew Lawrence Taylor on 19 November 2021, trading 2,000 units of MOTS stock currently worth $1,020.
motus gi holdings, inc. (nasdaq: mots) is a medical technology company based in the u.s., with subsidiaries in the u.s. and israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. the company is focused on the development and commercialization of the pure-vu® system, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. the pure-vu® system is a 510(k) u.s. food and drug administration cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. the device integrates with standard colonoscopes to enable cleaning during the procedure while preserving standard procedural workflow and techniques. the pure-vu® system has received ce mark approval in europe.
Motus GI Inc executives and other stock owners filed with the SEC include: